Q&A: BioNTech co-founders discuss immuno-oncology efforts, Bristol Myers deal

This week, BioNTech presented the industry’s most in-depth look so far at how PD-(L)1xVEGF bispecifics are being developed in cancer at its R&D Day in New York City. Following the event, ...